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Abstract
The mechanism of nitrogenase remains enigmatic, with a major unresolved issue concerning how 
inhibitors and substrates bind to the active site. We report a crystal structure of carbon monoxide 
(CO) inhibited nitrogenase MoFe-protein at 1.50 Å resolution, revealing a CO molecule bridging 
Fe2 and Fe6 of the FeMo-cofactor. The μ2 binding geometry is achieved by replacing a belt-sulfur 
atom (S2B) and highlights the generation of a reactive iron species uncovered by the displacement 
of sulfur. The CO inhibition is fully reversible as established by regain of enzyme activity and 
reappearance of S2B in the 1.43 Å resolution structure of the reactivated enzyme. The substantial 
and reversible reorganization of the FeMo-cofactor accompanying CO binding was unanticipated 
and provides insights into a catalytically competent state of nitrogenase.
Biological nitrogen fixation is Nature‘s pathway to convert atmospheric dinitrogen (N2) into 
a bioavailable form, ammonia (NH3). Nitrogenase, the only known enzyme capable of 
performing this multi-electron reduction, consists of two component metalloproteins, the Fe- 
(Av2) and MoFe- (Av1) protein (1–3). The Fe-protein, containing a [4Fe:4S]-cluster, 
mediates the adenosine triphosphate (ATP) dependent electron transfer to the MoFe-protein 
to support dinitrogen reduction (4). The MoFe-protein is an α2β2 heterotetramer with one 
catalytic unit per αβ heterodimer (5). To achieve the elaborate redox properties required for 
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reducing the N-N triple bond, two metal centers are present in the MoFe-protein: the P-
cluster and the FeMo-cofactor. The P-cluster, an [8Fe:7S] entity, is the initial acceptor for 
electrons, donated from the Fe-protein during complex formation between the two proteins 
(6–8). Electrons are subsequently transferred to the FeMo-cofactor, a [7Fe:9S:C:Mo]-R-
homocitrate cluster that constitutes the active site for substrate reduction, and is the most 
complex metal center known in biological systems (5, 9–12).
Substrates and inhibitors bind only to forms of the MoFe-protein reduced by two to four 
electrons relative to the resting, "as-isolated" state, which can only be generated in the 
presence of reduced Fe-protein and ATP (1). Mechanistic studies must take into account the 
dynamic nature of the nitrogenase system, requiring multiple association and dissociation 
events between the two component proteins, as well as the ubiquitous presence of protons 
that are reduced to dihydrogen even in competition with other substrates (1, 13–15). The 
resulting distribution of intermediates under turnover conditions significantly complicates 
the structural and spectroscopic investigation of substrate interactions. Hence, even the 
fundamental question whether molybdenum or iron represents the site for substrate binding 
at the FeMo-cofactor is still under debate, and as a consequence, a variety of mechanistic 
pathways have been proposed based on either molybdenum or iron as the catalytic center 
mainly following Chatt-type chemistry (16).
Inhibitors are potentially powerful tools for the preparation of stably trapped transient states 
that could provide insight into the multi-electron reduction mechanism. In this regard, 
carbon monoxide (CO), a non-competitive inhibitor for all substrates except protons (17, 
18), has a number of attractive properties; CO is isoelectronic to the physiological substrate, 
is a reversible inhibitor, and only binds to partially reduced MoFe-protein generated under 
turnover conditions. While non-competitive inhibitors are traditionally considered to bind at 
distinct sites from the substrate, for complex enzymes such as nitrogenase with multiple 
oxidation states and potential substrate binding modes, this distinction is not required (19). 
More recently, it has also been shown that CO is a substrate, albeit a very poor one, whose 
reduction includes concomitant C-C bond formation to generate C2 and longer-chain 
hydrocarbons, in a reaction reminiscent of the Fischer-Tropsch synthesis (20, 21). Therefore, 
CO binding as inhibitor/substrate must involve important active site properties common to 
the reduction of the natural substrate dinitrogen. For this reason, CO binding has been 
investigated by a variety of spectroscopic methods, most notably EPR and IR, and 
depending on the partial pressure, multiple CO-bound species have been observed; yet, a 
structurally explicit description of any CO binding site has been elusive (18, 22–27).
Building on these observations, we have determined a high-resolution crystal structure of a 
CO-bound state of the MoFe-protein from Azotobacter vinelandii. This necessitated 
overcoming several obstacles. First, the experimental setup for all protein handling steps, 
including crystallization, was deemed to require the continuous presence of CO. Second, 
because inhibition requires enzyme turnover, a prerequisite was the ability to obtain crystals 
of the MoFe-protein from activity assay mixtures, rather than from isolated protein (see 
supplementary material for assay details), conditions that are typically contradictory to 
crystallization requirements. Finally, rapid MoFe-protein crystallization (≤ 5 hrs) was 
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crucial and was achieved based on previously developed protocols in combination with 
seeding strategies, while maintaining the presence of CO throughout this process (10).
Crystals of the inhibited MoFe-protein (Av1-CO) yielded structural data at 1.50 Å 
resolution, which allowed clear identification of a CO ligand (Figure 1A, C, S1A–D). The 
Av1-CO structure directly demonstrates the binding of one molecule CO per active site in a 
μ2-bridging mode between Fe2 and Fe6 that form one edge of the trigonal six-iron prism 
(Fe2-3-4-5-6-7) of the FeMo-cofactor (Fig. 1A, C, D). Remarkably, CO binding is 
accompanied by a displacement of one of the belt sulfur atoms (S2B) while retaining the 
essentially tetrahedral coordination spheres for Fe2 and Fe6. As a result, the two Fe are 
coordinated by two sulfur and two carbon atoms, a geometry, to our knowledge, not 
previously observed in metallo-clusters (although higher coordination number geometries 
have been observed in FeFe-hydrogenases (28)). Confirmation of the S2B displacement was 
provided by anomalous difference Fourier maps calculated with diffraction data measured at 
7100 eV (Fig. 1B); this energy is just below the Fe K-edge so that the anomalous scattering 
from S is significantly enhanced relative to Fe. The carbon atom of CO is located at a 
distance of 1.86 Å from each of the irons (Fe2 and Fe6), compared to a previous distance of 
2.2 Å for S2B (Figure 1C). The altered ligand environment results in a small adjustment of 
the FeMo-cofactor geometry, with the Fe2–Fe6 distance (2.5 Å) slightly shortened relative 
to the unchanged Fe4–Fe5 and Fe3–Fe7 distances (2.6 Å) (Figure 1C).
Given the complete displacement of S2B, we assessed whether the CO-inhibited protein 
could be reactivated or if it was irreversibly modified. Crystals of CO-inhibited MoFe-
protein were active when dissolved in an assay mixture in the absence of CO. Furthermore, 
when CO-inhibited MoFe-protein from the original inhibition preparations was newly 
assayed after removal of CO (see supplementary material for assay details), a quantitative 
recovery (94 ± 4 %) of the initial activity was obtained (Table 1). The reactivated MoFe-
protein was subsequently re-isolated from activity assay mixtures and crystallized, yielding 
a structure at 1.43 Å resolution. The structural data of the protein (Av1-reactivated) revealed 
that S2B is regained by replacing the previously bound CO-ligand, which results in the 
recovery of the resting state FeMo-cofactor. The full occupancy of the sulfur at the S2B-site 
in the reactivated enzyme is evident by inspecting the 2Fo-Fc electron density map as well as 
the anomalous electron density map verifying the anomalous scattering contribution 
expected for S2B (Figure 2A, B).
The finding that S2B can be reversibly replaced by CO raises the question of where this 
atom is located in the CO-inhibited state. If the S2B binding site is ordered, candidate 
locations should be evident by an inspection of the 7100 eV anomalous difference Fourier 
map. In this manner, one site per catalytic unit was identified with anomalous density 
compatible with sulfur. This potential sulfur binding site (SBS) is positioned ~22 Å away 
from the S2B position in the FeMo-cofactor and consists of a small protein pocket at the 
interface of the α- and β-subunits, formed by the side chains of residues α-Arg93, α-Thr104, 
α-Thr111, α-Met112, β-Asn65, β-Trp428, β-Phe450 and β-Arg453 (Figure 3A, B). The 
positive surface charge of the cavity is suited to accommodate an anionic species such as 
HS− or S2− (Figure 3B). In previous structures of the resting state enzyme (pdb-IDs: 1M1N 
and 3U7Q), this site has been assigned as water; intriguingly, the density at this site is also 
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decreased in the structure of reactivated Av1 (Figure S2). The potential SBS is connected to 
the FeMo-cofactor binding pocket by a non-continuous water channel, and conformational 
rearrangements would be needed to accommodate the reversible migration of S2B from and 
to the active site. Although we have observed a correlation between density at the potential 
SBS and the CO-inhibited state of the MoFe-protein, the identity of this site as the displaced 
S2B cannot be achieved solely based on crystallographic data. In assessing the relevance of 
this site, it should be noted that the residues forming the pocket are poorly conserved, the 
site seems rather remote from the FeMo-cofactor, and since sulfur and chloride have similar 
anomalous scattering properties at 7100 eV, it is possible that this is a general anion-binding 
site in Av1.
The crystallographic characterization of CO-bound FeMo-cofactor of the MoFe-protein has 
important implications for the mechanism of substrate reduction by nitrogenase:
The CO binding site is close to the side chains of residues α-His195 (2.8 Å, NE2-OC 
distance) and α-Val70 (3.4 Å, closest methyl-OC distance). Modifications to both side 
chains were reported to significantly alter the catalytic properties of the enzyme. An α-
His195 to α-Gln195 mutation resulted in the loss of N2 reduction activity while an α-Val70 
to α-Ala/Gly70 alteration was reported to enable the reduction of longer carbon-chain 
substrates such as propyne and 1-butyne, respectively (29–33). In the structure presented 
here, α-His195 is in hydrogen bonding distance to the oxygen of CO while α-Val70 directly 
flanks the binding site (Figure 1D).
The displacement of S2B could be facilitated by a proton donation from α-His195 to yield 
either HS− or H2S, thereby generating a better leaving group than S2−. Although the 
dissociation of a sulfur may seem surprising, it opens up the ligand binding site, since the 
large radius of S2− effectively shields the cofactor Fe atoms in the resting state from 
substrate/inhibitor attack (2). The more general implication that binding of exogenous 
ligands can be accompanied by the reversible dissociation of at least one belt-sulfur from the 
metal sites of the FeMo-cofactor, changes the present view of the structural inertness of the 
[7Fe:9S:C:Mo]-R-homocitrate cluster towards ligand exchange. The relative lack of 
reactivity of the resting state is a striking property of the FeMo-cofactor, and the 
requirement for more highly reduced forms to bind substrate and inhibitors may reflect the 
need to dissociate sulfur ligands from Fe sites.
The displacement of the belt sulfur S2B by carbon monoxide causes the FeMo-cofactor 
scaffold to lose its intrinsic three-fold symmetry. Additionally, Fe1, the interstitial carbon 
and molybdenum are no longer aligned, creating an asymmetry in the resulting [7Fe:
8S:C:Mo] cluster (Figure 1C). The modest adjustments of the remaining scaffold upon CO 
binding are suggestive of an important role for the interstitial carbon in stabilizing the 
cofactor during rearrangements and substitutions to the coordination environment of the 
irons (34, 35).
The experimental manipulations used to generate the CO-inhibited structure are distinct 
from those reported in previous spectroscopic studies; hence it is not possible to 
unambiguously assign the structure to one of the many annotated spectroscopic states. 
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Interestingly, many of the previously identified states undergo dynamic interchanges 
including photoinduced transitions between states (25). Like the structure presented here, the 
spectroscopically identified “lo-CO” state has been proposed to involve one molecule of CO 
bound to the active site in a bridging mode (22, 26). A state with two CO bound to Fe2 and 
Fe6 could correspond to the “high-CO” form (22, 23) and might represent an intermediate 
relevant to the C-C coupling reaction.
The generation and successful stabilization of CO-bound MoFe protein under turnover 
conditions has culminated in a crystal structure that provides a detailed view of a ligand 
bound to the nitrogenase active site. The observations that CO is isoelectric to N2, is a potent 
yet reversible inhibitor of substrate reduction without impeding proton reduction to 
dihydrogen, and is bound in close proximity to previously determined catalytically 
important residues emphasizes the relevance of the CO-bound structure towards 
understanding dinitrogen binding and reduction. This sheds light on N2 activation based on a 
di-iron edge of the FeMo-cofactor and in this respect resembles the Haber-Bosch catalyst 
that also uses an iron surface to break the N-N triple bond. The demonstrated structural 
accessibility of CO-bound MoFe-protein opens the door for comparable studies on a variety 
of inhibitors and substrates, with the goal of understanding the detailed molecular 
mechanism of dinitrogen reduction by nitrogenase.
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Figure 1. CO-inhibited MoFe-protein (Av1-CO)
Refined structure of the CO-bound FeMo-cofactor at a resolution of 1.50 Å. A) View along 
the Fe1-C-Mo direction. The electron density (2Fo-Fc) map is contoured at 4.0 σ and 
represented as blue mesh. The density at the former S2B site is significantly decreased and 
in excellent agreement with bound CO (see also C)). B) Same orientation as A) 
superimposed with the anomalous density map calculated at 7100 eV (green) at a resolution 
of 2.1 Å contoured at 4.0 σ showing the significant reduction of anomalous electron density 
at the CO site. C) Side view of FeMo-cofactor highlighting the μ2 binding geometry of CO. 
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The electron density (2Fo-Fc) map (blue mesh) surrounding CO-Fe2-Fe6-C is contoured at 
1.5 σ. D) Same orientation as C) highlighting the ligand environment of the metal center. 
The catalytically important side chain residues α-Val70 and α-His195 are in close proximity 
to the CO-binding site. Iron atoms are shown in orange, sulfur in yellow, molybdenum in 
turquoise, carbon in grey, nitrogen in blue and oxygen in red.
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Figure 2. Reactivated MoFe-protein (Av1-reactivated)
Refined structure of the FeMo-cofactor at a resolution of 1.43 Å. A) View along the Fe1-C-
Mo direction. The electron density (2Fo-Fc) map is contoured at 4.0 σ and represented as 
blue mesh. Electron density at the S2B site is in excellent agreement with a regained sulfur. 
B) Same orientation as A) superimposed with the anomalous density map (green) at a 
resolution of 2.15 Å contoured at 4.0 σ showing the presence of anomalous density at the 
S2B site. Color scheme is according to Figure 1.
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Figure 3. Overview of the potential sulfur binding site (SBS) in the CO-inhibited MoFe-protein 
(Av1-CO)
A) Location of the potentially bound sulfur in a protein cavity on the interface between the 
α- and β-subunit of the α2β2 MoFe-protein. The potential SBS is located 22 Å away from its 
former position in the FeMo-cofactor (S2B-site). B) Close-up view on the binding cavity. 
Positive surface charge is represented in blue, negative surface charge in red. The anomalous 
density map at a resolution of 2.1 Å is represented as green mesh and contoured at 4.0 σ 
showing the presence of anomalous density at the potential SBS. The side chain sulfur of α-
Met112 provides an internal standard for full occupancy. The color scheme is according to 
Figure 1.
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Table 1
Nitrogenase activity
The acetylene reduction activity of “as-isolated” Av1, Av1-CO and Av1-reactivated was measured by the 
quantification of ethylene production. Nitrogenase activity is quantitatively recovered upon reactivation. 
Errors represent standard deviations of three measurements.
Sample Specific reduction activity
[nmol(acetylene) min−1 mg(Av1)−1]
Specific reduction activity
[%]
Av1-as-isolated 1930 ± 90 100 ± 5
Av1-CO < 2 ± 2 < 0.1 ± 0.1
Av1-reactivated 1820 ± 80 94 ± 4
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